Terumo (OTCMKTS:TRUMY) Rating Increased to Hold at Nomura

Nomura upgraded shares of Terumo (OTCMKTS:TRUMY) to a hold rating in a report issued on Tuesday,Zacks.com reports.

Terumo Trading Up 2.7%

TRUMY opened at $13.19 on Tuesday. Terumo has a 1-year low of $12.15 and a 1-year high of $20.12. The stock has a market capitalization of $19.46 billion, a PE ratio of 22.74 and a beta of 0.74. The company has a current ratio of 2.51, a quick ratio of 1.46 and a debt-to-equity ratio of 0.07. The firm has a 50-day moving average price of $13.84 and a two-hundred day moving average price of $15.64.

Terumo (OTCMKTS:TRUMY) last released its quarterly earnings results on Friday, February 13th. The company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.15 by ($0.01). Terumo had a net margin of 11.74% and a return on equity of 9.13%. The company had revenue of $1.94 billion for the quarter, compared to the consensus estimate of $1.82 billion.

About Terumo

Terumo Corporation (OTCMKTS: TRUMY) is a Japan-based medical technology company that develops, manufactures and markets a broad range of healthcare products for hospitals, clinics and blood centers. Its businesses encompass cardiovascular systems, general hospital products and blood management and cell technologies, supplying devices used in interventional and surgical procedures as well as everyday clinical care. Terumo sells consumables and capital equipment intended to support patient care across acute and ambulatory settings.

Key product categories include vascular access and interventional devices (such as guidewires, catheters and delivery systems), cardiac and cardiopulmonary surgical equipment, infusion therapy products (including infusion pumps and disposables), syringes and blood bags.